|Title:||Effect of prolonged HAART on oral colonization with Candida and candidiasis||Authors:||Yang Y.-L.
|Issue Date:||2006||Journal Volume:||6||Start page/Pages:||8||Source:||BMC Infectious Diseases||Abstract:||
Background: Progressive cell-mediated immunodeficiency with decrease of CD4+ lymphocyte count to less than or equal to 200 cells/mm3 is a major risk factor for colonization with Candida species and development of candidiasis. Oropharyngeal candidiasis may occur in up to 90% of human immunodeficiency virus (HIV)-infected patients during the course of the disease. This study is to determine the effect of prolonged highly active antiretroviral therapy (HAART) on oropharyngeal colonization with Candida species and oral candidiasis. Methods: A prospective, longitudinal follow-up study in HIV-infected patients receiving HAART. Results: The mean CD4+ count increased from 2 32.5 to 316 cells/mm3 and the proportion of patients whose CD4+ count less than 200 cells/mm3 decreased from 50.0% to 28.9% (p = 0.0003) in patients receiving HAART for at least 2 years. The prevalence of oral candidiasis decreased from 10.6% to 2.1% (p = 0.004). The decrease in Candida colonization was less impressive, falling from 57.8% to 46.5% (p = 0.06). Of the 142 patients enrolled in at least two surveys, 48 (33.8%) remained colonized with Candida and 42 (29.6%) remained negative. In the remaining 52 patients, 34 switched from culture positive to negative, and an increase in CD4+ lymphocytes was noted in 91.2% of them. Among the 18 patients who switched from culture negative to positive, 61.1% also demonstrated an increase in CD4+ lymphocyte count (p = 0.01). Conclusion: These findings indicate that HAART is highly effective in decreasing oral candidiasis in association with a rise in CD4+ lymphocyte counts, but only marginally effective in eliminating Candida from the oropharynx. ? 2006 Yang et al; licensee BioMed Central Ltd.
|ISSN:||1471-2334||DOI:||10.1186/1471-2334-6-8||SDG/Keyword:||antibiotic agent; antifungal agent; antiretrovirus agent; CD4 antigen; chloramphenicol; gentamicin; anti human immunodeficiency virus agent; antiinfective agent; article; Candida; clinical trial; controlled clinical trial; controlled study; culture medium; drug response; follow up; fungal colonization; health survey; highly active antiretroviral therapy; human; Human immunodeficiency virus infection; long term care; longitudinal study; lymphocyte count; major clinical study; prospective study; statistical analysis; statistical significance; thrush; virus load; adult; AIDS related complex; Candida; CD4 lymphocyte count; drug administration; drug effect; female; highly active antiretroviral therapy; Human immunodeficiency virus infection; isolation and purification; male; microbiology; oropharynx; physiology; risk factor; Adult; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; Candida; Candidiasis, Oral; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; Humans; Longitudinal Studies; Male; Oropharynx; Prospective Studies; Risk Factors
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.